Abstract
Ponatinib is approved for adults with refractory CML or Ph+ ALL and those with the T315I mutation. Recommended starting dose is 45 mg/day. Post hoc dose-response analyses from the registrational PACE trial suggest lower doses may mitigate safety risk while maintaining response; outcomes with lower doses have not been evaluated in clinical practice.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
